

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Canakinumab for untreated Schnitzler syndrome ID4063

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Novartis Pharmaceuticals (canakinumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Arthritis Action • Arthritis and Musculoskeletal Alliance • Autoinflammatory UK • Genetic Alliance UK • National Rheumatoid Arthritis Society • Rare Autoinflammatory Conditions Community - UK • South Asian Health Foundation • Specialised Healthcare Alliance • Versus Arthritis <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Anaemia Nurse Specialist Association • British Association of Dermatologists • British Committee for Standards in Haematology • British Dermatological Nursing Group • British Geriatrics Society • British Society for Genetic Medicine • British Society for Haematology • British Society for Rheumatology • Immunodeficiency UK • Primary Care Dermatology Society • Primary Care Rheumatology and Musculoskeletal Medicine Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord-UK (hydroxychloroquine) • Blackrock Pharmaceuticals Limited (hydroxychloroquine) • Bristol Laboratories (hydroxychloroquine) • Healthy Life Pharmaceuticals (pefloxacin) • Ipca Laboratories UK (hydroxychloroquine) • Swedish Orphan Biovitrum (anakinra) • Wockhardt UK (colchicine) • Zentiva (hydroxychloroquine) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Epidermo-Epidemiology Society

Provisional stakeholder list for the evaluation of canakinumab for untreated Schnitzler syndrome ID4063
Issue date: July 2022

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • CAPS and other Autoinflammatory Diseases National Treatment Service, The National Amyloidosis Centre (part of the UCL Division of Medicine, based at the Royal Free Hospital London) • Department of Clinical Immunology and Allergy, St James' University Hospital, Leeds • Department of Health and Social Care • NHS Bromley CCG • NHS England • NHS North Durham CCG • Welsh Government 	<ul style="list-style-type: none"> • British Skin Foundation • Cochrane UK • Cochrane Skin Group • Dermatrust • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

¹ Non company consultees are invited to submit statements relevant to the group they are representing.

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.